Emergent BioSolutions to Acquire Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From GSK
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement with GSK (LSE/NYSE: GSK), one of the world’s leading healthcare companies, to acquire raxibacumab, a...
Emergent BioSolutions to Acquire ACAM2000® Business From Sanofi
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement to acquire the ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) business of Sanofi in an all-cash...
Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 25, 2017 at 9:00 AM EDT; Webcast Will be Available
Emergent BioSolutions Inc. (NYSE:EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 25, 2017 beginning at 9:00 AM EDT at the Gaithersburg Marriott Washingtonian...
Emergent BioSolutions Unveils Its Expanded Center for Innovation in Advanced Development and Manufacturing in Baltimore
Emergent BioSolutions Inc. (NYSE:EBS) today held a ribbon-cutting ceremony led by Dr. Rick Bright, director of the Biomedical Advanced Research and Development Authority (BARDA), and Daniel J....
Emergent BioSolutions to Unveil its Expanded Center for Innovation in Advanced Development and Manufacturing Supported through Public-Private Partnership with BARDA
112,000-Square-Foot Baltimore Facility Is Designed to Enable Surge Manufacturing of Medical Countermeasures to Address Urgent Public Health Threats ADVISORY, May 09, 2017 (GLOBE NEWSWIRE) —...
Emergent BioSolutions Reports First Quarter 2017 Financial Results; Reaffirms 2017 Guidance
Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and three months ended March 31,...
Emergent BioSolutions to Release First Quarter 2017 Financial Results and Conduct a Conference Call on May 4, 2017
Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, May 4, 2017 at 5:00 pm (Eastern Time) to discuss the financial results for the first quarter of 2017, recent business...
Emergent BioSolutions Signs $53 Million Modification to BARDA Contract for the Manufacture of Botulism Antitoxin
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has signed a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) to manufacture and...
Emergent BioSolutions Awarded $100 Million BARDA Contract for BioThrax Deliveries to the Strategic National Stockpile
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has signed a two-year contract with the Biomedical Advanced Research and Development Authority (BARDA), a division within the Office of...
Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2016 Financial Results; Reaffirms 2017 Guidance and Provides 2020 Goals
Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and twelve months ended December 31,...
Emergent BioSolutions Receives BARDA Task Order Valued at Up to $30.5 Million to Develop Viral Hemorrhagic Fever Therapeutics
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has received a task order from the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $30.5 million to...
Emergent BioSolutions to Release Fourth Quarter and Full Year 2016 Financial Results and Conduct a Conference Call on February 23, 2017
Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, February 23, 2017 at 5:00 pm (Eastern Time) to discuss the financial results for the fourth quarter and full twelve...